October 25, 2021
Factor Bioscience Joins Strategic Partner Brooklyn ImmunoTherapeutics to Ring the Nasdaq Closing Bell
CAMBRIDGE, Mass., Oct. 25, 2021 — The executive leadership of Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies joined the leadership of Factor’s strategic partner, Brooklyn ImmunoTherapeutics (Nasdaq: BTX) today at the Nasdaq MarketSite in Times Square, New York, for the ringing of the Nasdaq closing bell by Brooklyn’s President and CEO, Howard J. Federoff, M.D., Ph.D. Factor Bioscience was represented by Co-Founder, Chairman, and CEO, Matt Angel, Ph.D., and Co-Founder and Chief Technology Officer, Christopher Rohde, Ph.D., while the Brooklyn team included Jay Sial, Chief Administrative Officer, Roger Sidhu, M.D., Chief Medical Officer, Ron Guido, M.S., M.S. Pharm. Med., Chief Development Officer, and Lynn Sadowski-Mason, M.S., EVP Clinical Operations.
October 21, 2021
Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of iPSC-Derived mRNA-Engineered NK Cells
CAMBRIDGE, Mass., Oct. 21, 2021 /PRNewswire/ — Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis’ innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer. The partnership also includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM, which will be used to fund operations.
September 15, 2021
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) – Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer and President Howard J. Federoff, M.D., Ph.D., will participate in the grand opening and ribbon cutting ceremony for its mRNA Cleanroom facility shared with Factor Bioscience in Cambridge, Mass.
September 9, 2021
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts
CAMBRIDGE, Mass., Sept. 15, 2021 /PRNewswire/ — Factor Bioscience Inc., a biotechnology company headquartered in Cambridge, Massachusetts, celebrated its tenth anniversary on September 9, 2021, with the grand opening of its new ISO Class 7 cleanroom facility at its headquarters near Inman Square. The new facility allows Factor and its strategic partners to produce advanced mRNA, gene-editing, and cell-therapy products for all phases of clinical development.
July 20, 2021
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
New York – July 19, 2021 – Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it had completed, on July 16, 2021, its acquisition of Novellus Therapeutics Limited (“Novellus”). Novellus is developing next‑generation engineered mesenchymal stem cell (“MSC”) therapies using extensively patented mRNA-based cell reprogramming and gene editing technologies licensed from Factor Bioscience (“Factor”).
July 1, 2021
Exacis Biotherapeutics Makes Strategic Investment In Manufacturing by Hiring Head of Technical Operations and Securing Space in a GMP Cleanroom Facility Recently Completed by Factor Bioscience
CAMBRIDGE, Mass., July 1, 2021 /PRNewswire/ — Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced two significant advances in its manufacturing capabilities. Exacis is partnering with parent Factor Bioscience to produce its iPSC-derived CAR-T and NK cells within a GMP cleanroom facility built by Factor, and Exacis has hired Bryan Jones PhD as its Head of Technical Operations.
For media inquiries and interview requests, please contact:
Allen Mireles
allen.mireles@scistories.com